All Companies

HALOCongressional Stock Trades

Halozyme Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)

Congressional stock trades in Halozyme Therapeutics, Inc. (HALO) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.

Total Trades

2

Politicians Trading

1

Last Traded

Sep 29, 2026

Trading History

PoliticianNotifiedTradedTypeAmountChange
Gilbert Ray Cisneros, Jr.DOct 12, 2026Sep 29, 2026Sell$1,001 - $15,000+15.59%
Gilbert Ray Cisneros, Jr.DApr 7, 2025Mar 24, 2025Sell$1,001 - $15,000+101.42%

Price History

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

FAQ

1 members of Congress have disclosed 2 trades in Halozyme Therapeutics, Inc. (HALO). Most active: Gilbert Ray Cisneros, Jr. (2).

Across all disclosures, members of Congress reported 0 purchases and 2 sales of Halozyme Therapeutics, Inc. (HALO). The most recent trade was on Sep 29, 2026.

Gilbert Ray Cisneros, Jr. disclosed selling Halozyme Therapeutics, Inc. (HALO) on Sep 29, 2026, valued at $1,001 - $15,000.

From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.